공고 • Jul 23
Evolus, Inc. to Report Q2, 2026 Results on Aug 05, 2026 Evolus, Inc. announced that they will report Q2, 2026 results After-Market on Aug 05, 2026 공고 • May 11
Evolus, Inc. Launches Estyme Injectable Hyaluronic Acid Gels Collection in Europe Evolus, Inc. announced that the commercial launch of Estyme (pronounced “esteem”), its injectable hyaluronic acid (HA) gel collection in Europe, is scheduled for May 16th, marking the company’s entry into the international dermal filler market. The Estyme collection includes four injectable HA gels that will cover a wide range of applications. The collection includes Estyme Smooth and Estyme Form, which are currently marketed in the United States under the brand Evolysse, along with the debut of two products including Estyme Lips and the flagship product in the line, Estyme Sculpt, which is expecting U.S. FDA approval later this year. Developed for restoring mid-face volume, Estyme Sculpt addresses one of the most in-demand treatment areas in aesthetics. Designed by Symatese, the innovative Cold-X technology helps preserve the natural structure of the HA molecule, providing long-lasting, natural-looking results. 공고 • May 06
Evolus, Inc. Reiterates Earnings Guidance for the Full Year 2026 Evolus, Inc. reiterated earnings guidance for the full year 2026. For the period, the company expects net revenue Guidance of $327 Million to $337 Million. 공고 • May 04
Evolus, Inc., Annual General Meeting, Jun 11, 2026 Evolus, Inc., Annual General Meeting, Jun 11, 2026. 공고 • Apr 14
Evolus, Inc. to Report Q1, 2026 Results on May 04, 2026 Evolus, Inc. announced that they will report Q1, 2026 results After-Market on May 04, 2026 공고 • Mar 04
Evolus, Inc. Provides Earnings Guidance for 2026 Evolus, Inc. provided earnings guidance for 2026. For the period, company's total net revenues are projected to be between $327 million and $337 million, representing 10% to 13% growth over the prior year. 공고 • Feb 17
Evolus, Inc. to Report Q4, 2025 Results on Mar 03, 2026 Evolus, Inc. announced that they will report Q4, 2025 results After-Market on Mar 03, 2026 공고 • Jan 09
Evolus, Inc. Reaffirms Preliminary Unaudited Earnings Guidance for the Fourth Quarter and Provides Preliminary Unaudited Earnings Guidance for the Year 2025 and Maintains Unaudited Earnings Guidance for the Year 2026 and Provides Earnings Guidance for the Year 2028 Evolus, Inc. reaffirmed preliminary unaudited earnings guidance for the fourth quarter and provided preliminary unaudited earnings guidance for the year 2025 and maintained unaudited earnings guidance for the year 2026 and provided earnings guidance for the year 2028. Total net revenues for the fourth quarter of 2025 are expected to be between $88.6 million and $90.6 million, a 12% to 15% increase over the fourth quarter of 2024, driven by higher volumes across all products.
Total net revenues for full-year 2025 are expected to be between $295.5 million and $297.5 million, an 11% to 12% increase over full-year net revenues in 2024. Evolysse™ injectable hyaluronic acid (HA) gels contributed approximately 8% of total revenue for the full-year 2025.
Total net revenues for 2026 are projected to be between $327 million and $337 million, which represents 11% to 13% growth from preliminary unaudited 2025 results. The company expects to achieve sustainable annual profitability beginning in 2026.
2028 long-term financial outlook reflecting total net revenue between $450 million and $500 million, representing a three-year CAGR of 15% to 19%, and non-GAAP operating income margins of 13% to 15% for 2028, which reflects: A recalibrated U.S. market outlook, reflecting current market conditions and a more conservative near-term growth environment; Strengthened market share, driven by continued outperformance, portfolio expansion, and commercial execution; and International business performance remaining on track, supported by continued execution across existing markets and the anticipated commercial launch of Estyme® in Europe. 공고 • Nov 06
Evolus, Inc. Reaffirms Earnings Guidance for the Full Year 2025 and 2028 Evolus, Inc. reaffirmed earnings guidance for the full year 2025. For the year, the company expects total net revenues to be between $295 million and $305 million, representing 11% to 15% growth over 2024 results. Total net revenue of $700 million by 2028. 공고 • Oct 22
Evolus, Inc. to Report Q3, 2025 Results on Nov 05, 2025 Evolus, Inc. announced that they will report Q3, 2025 results After-Market on Nov 05, 2025 공고 • Sep 23
Evolus, Inc. Announces National Launch of Revolutionary Evolysse Filler Line Evolus, Inc. has named Dr. Benjamin Eskenazi, MD, FACS, founder of Miami Beach's premier Avabello Aesthetics, as lead consultant for the national launch of their revolutionary Evolysse™? filler line. This partnership comes as Evolus introduces the first major technological breakthrough in hyaluronic acid dermal fillers in a decade, with Dr. Eskenazi providing critical expertise to support aesthetic providers nationwide. As lead consultant, Dr. Eskenazi will leverage his extensive experience in the injectable space and deep knowledge of facial anatomy to assist aesthetic providers should questions arise during treatment with the new Evolysse™? products. While not specifically mandated by the FDA or any regulatory agency, this collaboration showcases Evolus' proactive commitment to patient safety and provider support during the launch of their groundbreaking filler technology. The FDA recently approved Evolysse™? Form and Evolysse™? Smooth, marking Evolus' entry into the U.S. hyaluronic acid Dermal filler market. The revolutionary fillers utilize innovative Cold-X™? technology that preserves the natural structure of the hyaluronic acid molecule for longer-lasting, natural-looking results. Evolus specifically selected Dr. Eskenazi based on his distinguished track record as an aesthetic educator, expert injector, and recognized authority in facial aesthetics. Dr. Eskenazi brings over eight years of private practice experience and completed his plastic surgery training at the world-renowned Cleveland Clinic Foundation, gaining extensive expertise in both aesthetic and reconstructive procedures. The partnership positions Dr. Eskenazi as a key resource for aesthetic providers nationwide who may encounter questions or challenges during Evolysse™? treatments. His expertise will be available to support the medical community as they integrate this breakthrough technology into their practices. Avabello stands apart as one of the few medical spas in Miami Beach overseen by a board-certified plastic surgeon, ensuring that every treatment is performed with the highest level of medical expertise. This fundamental understanding of aesthetics brings unparalleled safety and effectiveness to the services offered at the practice. The Evolysse™? line represents a significant advancement in dermal filler technology, with clinical studies providing compelling evidence around their safety and efficacy. 공고 • Sep 08
Evolus, Inc. Appoints Tatjana Mitchell as Chief Financial Officer, Effective September 8, 2025 On September 8, 2025, Evolus, Inc. announced that, effective September 8, 2025, its Board of Directors appointed Tatjana Mitchell to serve as the Company’s Chief Financial Officer. Ms. Mitchell has over 20 years of strategic and operational finance leadership across both public and private companies in retail, consumer, data, and technology-driven businesses. She brings a proven track record of driving revenue growth, scaling organizations, and leading transformation efforts through disciplined financial management and strategic execution. Tatjana Mitchell, age 47, served as the Senior Vice President, Finance of Experian North America since April 2023. From May 2019 to March 2023, Ms. Mitchell served as the Chief Financial Officer for Experian North America Consumer Services. From December 2015 to May 2019, Ms. Mitchell served as the Vice President of Finance and Chief Financial Officer of Zulily and held finance leadership positions at Forever 21, Macy’s, Gap Inc., and Marriott International. She earned her MBA from The Wharton School at the University of Pennsylvania and a Bachelor of Science in Business Administration from Towson University. 공고 • Aug 26
Evolus Announces Positive Data from Pivotal Trial for Evolysse Sculpt Injectable Hyaluronic Acid Gel Product at 2025 Cosmetic Bootcamp Evolus, Inc. announced positive topline results from a U.S. pivotal study of Evolysse Sculpt, an injectable hyaluronic acid (HA) gel product designed to restore mid-face volume. The U.S. mid-face pivotal study was a multicenter, double-blinded, controlled, non-inferiority design. Patients were followed for 24 months from initial treatment. A total of 304 patients were enrolled and randomized to receive Evolysse Sculpt or Restylane-Lyft. The 6-month primary endpoint measured the mean grade change in mid-face volume deficit from baseline and was assessed by a blinded, live evaluator using a validated 5-point photo-numeric scale. The Evolysse Sculpt injectable HA gel product met its primary endpoint of non-inferiority and demonstrated statistical superiority versus Restylane-Lyft, with a mean mid-face volume deficit severity score difference of -0.26 (95% CI [ -0.45, -0.07; non-inferiority margin 0.5) and corresponding p-value of Cold-X and Estyme are trademarks of Symatese Group and Symatese Aesthetics S.A.S. 공고 • Aug 20
Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for Evolysse™? Sculpt Injectable Hyaluronic Acid Gel Product Evolus, Inc. announced that it has submitted the final module of its Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for Evolysse™? Sulpt, an injectable hyaluronic acid (HA) gel product designed to restore mid-face volume. Evolus anticipates that the FDA's review will follow the standard PMA process, with approval expected in the second half of 2026. The submission underscores Evolus' commitment to bringing its collection of injectable hyaluronic Acid gel products to market and its readiness to meet rigorous regulatory requirements. In support of the PMA application, a U.S. pivotal study which evaluated the safety and effectiveness of the product in a multicenter, double-blinded, controlled, non-inferiority designed trial was conducted. Patients were followed for 24 months from initial treatment. A total of 304 patients were enrolled and randomized to receive Evolysse™? Sculpt or Restylane®?-Lyft. 공고 • Aug 06
Evolus, Inc. Updates Earnings Guidance for the Full Year 2025 Evolus, Inc. updated earnings guidance for the full year 2025. For the period, Company expects Total net revenues to be between $295 million and $305 million, representing 11% to 15% growth over 2024 results. Company increases Evolysse injectable HA gels contribution to 10% to 12% of total revenue for the full-year 2025. 공고 • Aug 01
Evolus, Inc. Announces Publication of Independent Study in Jama Dermatology Demonstrating Jeuveau® as A Top Performer Among Leading Neurotoxins Evolus, Inc. announced the publication of a landmark independent study in JAMA Dermatology directly comparing four leading botulinum toxin type A products for the treatment of glabellar lines: Jeuveau® (prabotulinumtoxinA-xvfs), Botox®? (onabotulinumtoxin A), Dysport® (abobotulinumtoxinA), and Xeomin® (incobotulinumtoxin A). In the double-blind, randomized study conducted at the University of Pennsylvania, 143 female participants aged 30 to 65 were treated with FDA-approved doses of either Jeuveau®, Botox®, Dysport®, or Xeomin®. Using advanced 3-dimensional photogrammetry, researchers quantified dynamic facial strain to objectively measure efficacy at days 3, 30, 90, and 180. Key published findings include: Fast Onset of Action: Jeuveau® and Dysport®? demonstrated significantly faster visible effects at Day 3 compared to Botox® and Xeomin®. Strong Peak Effect: Jeuveau®? achieved the highest peak effect at Day 30, with a median strain reduction of 93%, highlighting its robust performance profile. Long Duration of Effect: Jeuveau®®? had significant duration at Day 180 compared with baseline and was significantly more effective than Botox® at this time point. Since its launch, Jeuveau® has become the fastest-growing neurotoxin in the U.S. for four consecutive years. Today, it holds over 14% U.S. market share and has penetrated over 50% of aesthetic clinics. Evolus provided funding for this study through an investigator-initiated research grant. As an independent study, Evolus was not involved in the design, protocol development, or in the conduct of the research, each of which was carried out independently by the investigators. 공고 • Jul 22
Evolus, Inc. to Report Q2, 2025 Results on Aug 05, 2025 Evolus, Inc. announced that they will report Q2, 2025 results After-Market on Aug 05, 2025 공고 • May 28
Evolus, Inc. Announces Resignation of Sandra Beaver as Chief Financial Officer, Effective June 13, 2025 Evolus, Inc. announced that its Chief Financial Officer, Sandra Beaver, has resigned effective June 13, 2025, to accept the same position at a private mental health and wellness technology company. Ms. Beaver’s resignation is not a result of any disagreement related to the company’s operations, policies, or practices, including any accounting principles and practices, or related to any financial statements or disclosures. The company has initiated a search to identify her successor and will provide updates as appropriate. In the interim, Evolus’ experienced Finance team will continue leading the accounting, finance, and investor relations functions to ensure a smooth transition. 공고 • May 22
Evolus Announces Publication of U.S. Pivotal Study for Evolysse Form and Evolysse Smooth Injectable Hyaluronic Acid Gels Evolus, Inc. announced the publication of the U.S. pivotal study results for Evolysse Form and Evolysse Smooth in the Aesthetic Surgery Journal, a leading peer-reviewed journal focusing on advances in aesthetic medicine and surgery. The multicenter, randomized, controlled, double-blind study followed 140 patients through 12 months and evaluated the long-term safety and effectiveness of Evolysse™? Form and Evolysse™? Smooth, Cold-X™? crosslinked injectable hyaluronic acid (HA) gels, for the correction of moderate to severe dynamic facial wrinkles and folds. Key published findings include: Statistical Superiority: Evolysse™? form and Evolysse™, the. 공고 • May 08
Evolus, Inc. Reaffirms Earnings Guidance for the Full Year 2025 Evolus, Inc. reaffirmed earnings guidance for the full year 2025. For the period, the company continues to expect total net revenues to be between $345 million and $355 million, representing 30% to 33% growth over 2024 results. 공고 • Apr 28
Evolus, Inc., Annual General Meeting, Jun 05, 2025 Evolus, Inc., Annual General Meeting, Jun 05, 2025. 공고 • Apr 23
Evolus, Inc. to Report Q1, 2025 Results on May 07, 2025 Evolus, Inc. announced that they will report Q1, 2025 results After-Market on May 07, 2025 공고 • Apr 16
Evolus, Inc. Announces Commercial Launch of Evolysse Evolus, Inc. announced the commercial launch date for Evolysse Form and Evolysse Smooth injectable hyaluronic acid (HA) gels, the first two products in the Evolysse collection, scheduled for April 18th. To support the introduction, Evolus will initiate a comprehensive educational rollout beginning with a national Evolysse Academy webcast for healthcare practitioners on April 18th with several thousand attendees expected to participate.head of the webcast, the company has already begun an early experience program by sending product to over 1,000 key accounts, including key opinion leaders (KOLs), clinical investigators, and leading practices. This approach enables providers to explore the performance and versatility of Evolysse injectable HA gels for the correction of dynamic facial wrinkles and folds, such as nasolabial folds, which will accelerate comfort, confidence, and integration of the products into clinical practice. The Evolysse collection marks the company's second commercial aesthetics product, following the successful launch of Jeuveau in 2019. Since its launch, Jeuveau has become the fastest-growing neurotoxin in the U.S. for four consecutive years and has now captured over 14% of the U.S. market and penetrated over 50% of aesthetic clinics. With over 15,000 purchasing accounts, Evolysse will launch into an established customer base who will gain access to Evolysse Form andEvolysse Smooth, helping to drive immediate and impactful momentum in the U.S. injectable HA market. 공고 • Apr 15
Evolus Launches "Drop the F Word" Campaign in Advance of the Commercial Launch of Evolysse™? Injectable Hyaluronic Acid Gels Evolus, Inc. announced the launch of its bold new campaign, "Drop the F Word," ahead of the upcoming commercial launch of Evolysse™?. Designed to challenge outdated perceptions and language in the aesthetics industry, the campaign introduces Evolysse™?, a collection of injectable hyaluronic acid (HA) gels specifically designed to deliver long-lasting, natural-looking results for the treatment of moderate to severe dynamic facial wrinkles and folds, such as nasolabial folds. The "Drop the F Word" campaign aims to reenergize the injectable HA category and address growing filler fatigue. Increasingly, consumers associate the term "filler" withnatural results and an overfilled look, perceptions that no longer reflect the advancement of today's products or consumer desires. In response, Evolus conducted in-depth research with customers and consumers to better understand these shifting attitudes. The insights were clear, "filler" is an outdated term and no longer serves the category. As a result, Evolus tested new ways to refram the category and is introducing Evolysse™? as a collection of injectable hyALuronic acid gels, removing "filler," the "F word," from its vernacular. This approach better reflects the innovation behind the collection and the results consumers expect today. With the first breakthrough in HA technology in over a decade, Evolysse™? marks a new chapter in aesthetic injectables, moving beyond the traditional concept of "fillers" and toward a new standard of personalized, natural-looking outcomes. Evolysse™? is manufactured utilizing Cold-X™? technology, an innovative manufacturing process designed to better preserve the natural structure of the HA molecule. The result is a collection of injectable HA gels that deliver natural-looking outcomes and align with the evolving expectations of today's aesthetic consumers. Through this initiative, Evolus is inviting patients, practitioners, and the broader beauty industry to rethink how aesthetic treatments are discussed, embraced, and delivered. The campaign also underscores the company's broader mission and modern approach to elevate the aesthetics experience, prioritizing confidence and informed decision-making across all stakeholders. With Evolysse™?., Evolus is not only launching an innovative injectable HA collection but also leading a cultural shift in how beauty treatments are perceived. This campaign and product launch together represent a commitment to advancing performance beauty that reflects the expectations of today's beauty consumer. 공고 • Mar 06
Evolus, Inc. Reaffirms Earnings Guidance for 2025 Evolus, Inc. reaffirmed earnings guidance for 2025. For the period, the company's Total net revenues are estimated to be between $345 million and $355 million, which represents 30% to 33% growth from 2024 results. Evolysse Estyme injectable hyaluronic acid (HA) gels are anticipated to contribute 8-10% of total revenue for the full-year 2025. 공고 • Feb 18
Evolus, Inc. to Report Q4, 2024 Results on Mar 04, 2025 Evolus, Inc. announced that they will report Q4, 2024 results After-Market on Mar 04, 2025 공고 • Feb 14
Evolus, Inc. Announces FDA Approval of Evolysse™? Form and Evolysse™? Smooth Injectable Hyaluronic Acid Gels Evolus, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Evolysse™? Form and Evolysse™? Smooth injectable hyaluronic acid (HA) gels, the first two products in the Evolysse™? collection. These approvals mark Evolus' entry into the U.S. HA dermal filler market and solidifies the company's position as a multi-product innovator in aesthetics, expanding Evolus' total addressable market by 78% to approximately $6 billion. Evolus plans to launch Evolus™? Form andEvolysse™? Smooth in the U.S. market in second quarter 2025. This launch will leverage Evolus' scalable cash-pay business model and existing digital infrastructure, creating tremendous synergy with the company's fast-growing neurotoxin business and driving significant value for both customers and consumers. Board Change • Feb 01
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. Independent Director Al White was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. New Risk • Jan 21
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company. 공고 • Jan 21
Evolus, Inc. Provides Financial Guidance for the Full Year of 2025 Evolus, Inc. provides financial guidance for the full year of 2025. For the period, the company total net revenues are estimated to be between $345 million and $355 million, which represents 30% to 33% growth from preliminary 2024 results. Evolysse™ and Estyme® injectable HA gels are anticipated to contribute 8-10% of total revenue for the full-year 2025. Reported Earnings • Nov 07
Third quarter 2024 earnings released: US$0.30 loss per share (vs US$0.30 loss in 3Q 2023) Third quarter 2024 results: US$0.30 loss per share (further deteriorated from US$0.30 loss in 3Q 2023). Revenue: US$61.1m (up 22% from 3Q 2023). Net loss: US$19.2m (loss widened 13% from 3Q 2023). Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 27% per year and the company’s share price has also increased by 27% per year. 공고 • Nov 07
Evolus, Inc. Provides Earnings Guidance for the Year 2024 Evolus, Inc. provided earnings guidance for the year 2024. For the year, the company narrows its full year total net revenue guidance to $260 million to $266 million, representing year-over-year growth of 29% to 32% from 2023 results and well above the estimated growth rate of the aesthetic neurotoxin market. 공고 • Nov 01
Evolus, Inc. Announces EU Approval of Estyme Injectable Hyaluronic Acid Gels Under New Medical Device Regulation Evolus, Inc. announced the EU Medical Device Regulation (MDR) certification was received for four unique injectable hyaluronic acid (HA) gels under the brand name Estyme® (pronounced “esteem”), branded as Evolysse in the U.S. market. This certification marks a key regulatory milestone for Evolus, enabling it to commercially enter the dermal filler segment and doubling its addressable market outside the U.S. to $1.8 billion. The CE Mark certification, through the new MDR process represents more stringent requirements, designed to ensure the safety, efficacy, and quality of medical devices sold in Europe. Achieving this certification demonstrates that the Estyme® injectable HA gels meet the highest standards for product design, production, and performance. Evolus will introduce Estyme® through a limited experience program with select physician partners. The limited experience program will allow Evolus to collaborate with leading aesthetic practitioners across Europe, gathering valuable insights to refine its broader launch strategy. A broader European launch is planned for the second half of 2025. The company remains on track for the U.S. approval and launch of the Evolysse™ injectable HA gels beginning in 2025. 공고 • Oct 23
Evolus, Inc. to Report Q3, 2024 Results on Nov 06, 2024 Evolus, Inc. announced that they will report Q3, 2024 results After-Market on Nov 06, 2024 New Risk • Aug 02
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.0% average weekly change). Shareholders have been diluted in the past year (11% increase in shares outstanding). Significant insider selling over the past 3 months (US$2.7m sold). Reported Earnings • Aug 01
Second quarter 2024 earnings released: US$0.18 loss per share (vs US$0.32 loss in 2Q 2023) Second quarter 2024 results: US$0.18 loss per share (improved from US$0.32 loss in 2Q 2023). Revenue: US$66.9m (up 36% from 2Q 2023). Net loss: US$11.4m (loss narrowed 37% from 2Q 2023). Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth. 공고 • Aug 01
Evolus, Inc. Raises Financial Guidance for the Full Year of 2024 Evolus, Inc. raised financial guidance for the full year of 2024. For the period, the company expects total net revenues to be between $260 million and $270 million, representing year-over-year growth of 34% at the top end. 공고 • Jul 17
Evolus, Inc. to Report Q2, 2024 Results on Jul 31, 2024 Evolus, Inc. announced that they will report Q2, 2024 results on Jul 31, 2024 공고 • Jul 01
Evolus, Inc. Appoints Albert G. White III to its Board of Directors and Compensation Committee Evolus, Inc. announced the appointment of Albert G. White III, President and Chief Executive Officer of The Cooper Companies, Inc. to the Evolus Board of Directors, effective July 1, 2024. Mr. White will also serve as a member of Evolus’ Compensation Committee. Mr. White has served as President & Chief Executive Officer of The Cooper Companies, Inc., branded CooperCompanies, since May 2018. Previously, he served as Chief Financial Officer from November 2016 until his appointment as CEO and he also served as Executive Vice President and Chief Strategy Officer, positions he held from December 2015 and July 2011, respectively. From August 2015 to May 2018, Mr. White also directed The Cooper Companies, Inc. women’s healthcare business and served as Chief Executive Officer of Cooper Medical Inc., the parent company to CooperSurgical. Previously, he served as Vice President, Investor Relations from November 2007 through March 2013 and as Vice President and Treasurer from April 2006 through December 2012. Prior to joining The Cooper Companies, Inc., Mr. White was a Director with KeyBanc Capital Markets for three years and held a number of leadership positions within KeyBank National Association over the prior eight years. Following these changes, Evolus’ Board of Directors will be composed of seven directors, six of whom are independent. 공고 • Jun 24
Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse™ Dermal Filler Products Evolus, Inc. announced that it has submitted the final module of its premarket approval (PMA) application to the U.S. Food and Drug Administration (FDA) for the Evolysse™ Lift and Evolysse™ Smooth dermal filler products for the nasolabial fold. Evolus anticipates that the FDA’s review process will adhere to the standard timeline, with approval expected in the second half of 2025. The submission underscores Evolus’ commitment to bringing the dermal filler products to market and its readiness to meet regulatory requirements. The PMA application includes results from the U.S. pivotal study, which evaluated the safety and effectiveness of the products in a multicenter, blinded, split face, controlled, non-inferiority designed trial. Patients were followed for 12 months from initial treatment. A total of 140 patients were enrolled and divided evenly across two investigational arms. Patients were randomized to receive Evolysse™ Lift or Evolysse™ Smooth in one NLF and Restylane-L in the contralateral NLF. This split face design allowed each individual patient to experience one of the Evolysse™ fillers and the control at the same time. Both the Evolysse™ Lift and Evolysse™ Smooth dermal filler products met their primary endpoint of non-inferiority and demonstrated superiority to Restylane-L at 6 months. The Evolysse™ Lift filler will be positioned as the most versatile for treating facial wrinkles and folds (such as NLFs) and is expected to be the highest use filler in the product line. The Evolysse™ Smooth filler will be positioned as an alternative softer formulation option to Evolysse™ Lift. Recent Insider Transactions • Jun 09
Chairman of the Board recently sold US$97k worth of stock On the 3rd of June, Vikram Malik sold around 8k shares on-market at roughly US$12.96 per share. This transaction amounted to 3.1% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth US$1.3m. Vikram has been a net seller over the last 12 months, reducing personal holdings by US$459k. 공고 • May 23
Evolus, Inc. Announces Positive Data from Pivotal Trial for First Two Evolysse™ Dermal Filler Products at 2024 SCALE Meeting Evolus, Inc. announced positive topline results from a U.S. pivotal nasolabial fold (NLF) study of dermal filler products Evolysse™ Lift and Smooth. Data were presented at the 2024 SCALE Meeting on May 17, 2024, in Nashville. Study Design: The U.S. NLF pivotal study was a multicenter, blinded, split face, controlled, non-inferiority design. Patients were followed for 12 months from initial treatment. A total of 140 patients were enrolled and divided evenly across two investigational arms. Patients were randomized to receive Evolysse™ Lift or Evolysse™ Smooth in one NLF and Restylane-L in the contralateral NLF. This split face design allowed each individual patient to experience one of the Evolysse™ fillers and the control at the same time. The 6-month primary endpoint measured the change in NLF severity from baseline and was assessed by a blinded independent photographic review panel using a validated 5-point nasolabial scale. Results: The Evolysse™ Lift vs Restylane-L arm met the primary endpoint of non-inferiority and demonstrated superiority, with a mean NLF severity score difference of -0.3 (95% CI: -0.500, -0.032, non-inferiority margin 0.5) and corresponding p-value of 0.03. As a secondary endpoint, the mean grade change in the NLF severity, as assessed by the blinded, live evaluator demonstrated a statistically significant difference (p<0.05) at all timepoints from 6 weeks to 12 months between Evolysse™ Lift and the control. The Evolysse™ Smooth vs Restylane-L arm also met the primary endpoint of non-inferiority and demonstrated superiority, with a mean NLF severity score difference of -0.2 (95% CI: -0.416, -0.019, non-inferiority margin 0.5) and corresponding p-value of 0.02. As a secondary endpoint, the mean grade change in the NLF severity, as assessed by the blinded, live evaluator demonstrated a statistically significant difference (p<0.05) at 6 and 9 months between Evolysse™ Smooth and the control. The safety profiles were similar between the two Evolysse™ dermal filler products compared to their respective controls and there were no treatment-related serious adverse events. Evolus remains on track to submit Premarket Approval (PMA) applications for the first two Evolysse™ dermal filler products with the FDA within the next 90 days. The Evolysse™ Lift filler will be positioned as the most versatile and highest use filler in the product line. The Evolysse™ Smooth filler is a softer product than Lift, providing additional versatility. Recent Insider Transactions • May 16
President recently sold US$204k worth of stock On the 10th of May, David Moatazedi sold around 16k shares on-market at roughly US$12.72 per share. This transaction amounted to 10% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth US$1.3m. David has been a net seller over the last 12 months, reducing personal holdings by US$2.7m. Breakeven Date Change • May 09
Forecast breakeven date moved forward to 2025 The 7 analysts covering Evolus previously expected the company to break even in 2026. New consensus forecast suggests losses will reduce by 20% to 2024. The company is expected to make a profit of US$5.17m in 2025. Average annual earnings growth of 66% is required to achieve expected profit on schedule. 공고 • May 09
Evolus, Inc. Reaffirms Financial Guidance for the Full Year 2024 Evolus, Inc. reaffirmed financial guidance for the full year 2024. The company continues to expect total net revenues for the full year 2024 to be between $255 million and $265 million, representing year-over-year growth of 31% at the top end. Reported Earnings • May 08
First quarter 2024 earnings released: US$0.22 loss per share (vs US$0.26 loss in 1Q 2023) First quarter 2024 results: US$0.22 loss per share (improved from US$0.26 loss in 1Q 2023). Revenue: US$59.3m (up 42% from 1Q 2023). Net loss: US$13.1m (loss narrowed 11% from 1Q 2023). Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 5.6% growth forecast for the Pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth. 공고 • Apr 24
Evolus, Inc. to Report Q1, 2024 Results on May 07, 2024 Evolus, Inc. announced that they will report Q1, 2024 results After-Market on May 07, 2024 공고 • Apr 18
Evolus, Inc. Announces Publication of Safety and Duration Data from Phase 2 Study for "Extra- Strength" 40U Formulation of Jeuveau Evolus, Inc. announced that the Aesthetic Surgery Journal has published the safety and duration of effect results from the Phase 2 study of 40U Jeuveau® (prabotulinumtoxinA-xvfs) for the treatment of moderate to severe glabellar lines in adult patients. The " extra-strength" glabellar line study is a multicenter, double-blind, randomized, Phase 2 trial following 150 patients for up to 12 months or until the patient loses their correction. The study has three arms: Jeuveau® Extra- strength 40U and two active controls, BOTOX 20U and Jeuveau 20U. 공고 • Apr 04
Evolus, Inc. Announces Board Changes In furtherance of Evolus, Inc.’s (the “Company’s”) Board of Directors (“Board”) refreshment efforts, on April 2, 2024, Robert Hayman and Simone Blank provided notice of their planned transition off of the Board of the Company. Mr. Hayman notified the Board that he will step down from his position on the successful identification and appointment of a replacement director. The Company intends to identify a suitable replacement director prior to its 2024 Annual Shareholder Meeting. Similarly, Ms. Blank notified the Board that she will step down from her position on the earlier of: (i) the Company’s Annual Shareholder Meeting occurring in 2025, or (ii) the successful identification and appointment of a replacement director, whichever occurs first. Both Mr. Hayman and Ms. Blank have made significant contributions to the Company during their tenure and the Company’s management and Board wish to express their appreciation for their dedicated service and thoughtful transition plans in furtherance of the Company’s board refreshment efforts. The Company is already in the process of searching for suitable replacements to fill these upcoming vacancies. Recent Insider Transactions • Mar 22
President recently sold US$1.3m worth of stock On the 19th of March, David Moatazedi sold around 97k shares on-market at roughly US$13.92 per share. This transaction amounted to 45% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. David has been a net seller over the last 12 months, reducing personal holdings by US$2.3m. 공고 • Mar 11
Evolus, Inc. has completed a Follow-on Equity Offering in the amount of $50.00478 million. Evolus, Inc. has completed a Follow-on Equity Offering in the amount of $50.00478 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 3,554,000
Price\Range: $14.07
Discount Per Security: $0.8442 공고 • Mar 08
Evolus, Inc. Reiterates Earnings Guidance for the Full Year 2024 Evolus, Inc. reiterated earnings guidance for the full year 2024. For the period, the company reiterated full year net revenue guidance of $255 million to $265 million, which represents 31% growth at the top end of the range. Reported Earnings • Mar 08
Full year 2023 earnings released: US$1.08 loss per share (vs US$1.33 loss in FY 2022) Full year 2023 results: US$1.08 loss per share (improved from US$1.33 loss in FY 2022). Revenue: US$202.1m (up 36% from FY 2022). Net loss: US$61.7m (loss narrowed 17% from FY 2022). Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 5.8% growth forecast for the Pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth. 공고 • Feb 23
Evolus, Inc. to Report Q4, 2023 Results on Mar 07, 2024 Evolus, Inc. announced that they will report Q4, 2023 results After-Market on Mar 07, 2024 공고 • Jan 17
Evolus, Inc. Announces Earnings Guidance for 2024 Evolus, Inc. announced earnings guidance for 2024. For the period, total net revenues for 2024 are estimated to be between $255 million and $265 million, which represents 26% to 31% growth from preliminary 2023 results. 공고 • Jan 05
Evolus, Inc. Appoints Nareg Sagherian as Head of Global Investor Relations and Corporate Communications Evolus, Inc. announced that Nareg Sagherian has joined the Company as Head of Global Investor Relations and Corporate Communications. In this role, Nareg will be responsible for interacting with current and prospective investors and managing a strategic investor relations and corporate communications program. Prior to joining Evolus, Nareg was the Executive Director, Head of Global Investor Relations, Corporate Affairs for Intercept Pharmaceuticals. Nareg brings extensive experience in capital markets, investor relations, corporate communications, and public policy to Evolus from firms including FTI Consulting, Biotechnology Innovation Organization and Booz Allen Hamilton. He also spent three years in the public sector at the U.S. Department of the Treasury and U.S. Small Business Administration. Nareg received an M.B.A. from the University of Virginia’s Darden School of Business, a Graduate Diploma in Legislative Studies from the Georgetown University Government Affairs Institute, a M.S. in Corporate Finance and a Graduate Diploma in Investments from the Johns Hopkins University Carey Business School, and a M.S. in Medical Sciences from the Wayne State University School of Medicine. New Risk • Dec 22
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.7% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Negative equity (-US$19m). Minor Risks Less than 1 year of cash runway based on current free cash flow (-US$46m). Shareholders have been diluted in the past year (2.7% increase in shares outstanding). Significant insider selling over the past 3 months (US$822k sold). Recent Insider Transactions • Dec 11
President recently sold US$822k worth of stock On the 8th of December, David Moatazedi sold around 83k shares on-market at roughly US$9.95 per share. This transaction amounted to 84% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. David has been a net seller over the last 12 months, reducing personal holdings by US$974k. New Risk • Nov 15
New minor risk - Insider selling There has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: US$197k This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Major Risk Negative equity (-US$19m). Minor Risks Less than 1 year of cash runway based on current free cash flow (-US$46m). Significant insider selling over the past 3 months (US$197k sold). New Risk • Nov 12
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$46m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$46m free cash flow). Negative equity (-US$19m). Breakeven Date Change • Nov 08
No longer forecast to breakeven The 7 analysts covering Evolus no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$5.29m in 2025. New consensus forecast suggests the company will make a loss of US$15.6m in 2025. 공고 • Nov 08
Evolus, Inc. Raises Earnings Guidance for the Full Year 2023 Evolus, Inc. raised earnings guidance for the full year 2023. For the year, the company now expects total net revenues to be between $194 million and $198 million from $185 Million to $195 Million, representing year-over-year growth of greater than 30% and magnitudes above the estimated growth rate of the aesthetic neurotoxin market. Board Change • Nov 08
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. Independent Director Brady Stewart was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. 공고 • Nov 07
Evolus, Inc. Announces Results from the Phase 2 Clinical Study Evaluating the "Extra- strength" 40U Dose for Extended Duration of Jeuveau Evolus, Inc. announced results from the Phase 2 clinical study evaluating the “extra-strength” 40U dose for extended duration of Jeuveau® (prabotulinumtoxinA-xvfs), the only neurotoxin dedicated exclusively to aesthetics. Final data were presented at the 2023 American Society for Dermatologic Surgery (ASDS) Annual Meeting on November 3, 2023, in Chicago, and demonstrated 26 weeks, or 6 months of duration with the extra-strength dose of 40U across multiple measurements. In the Phase 2 study, the “extra-strength” formulation using 40U of Jeuveau® was compared to active controls, the approved 20U of Jeuveau® and 20U of Botox®, looking at glabellar lines at maximum frown using the validated 4-point Glabellar Line Scale (GLS). Results demonstrated 26 weeks, or 6 months duration across the multiple metrics presented, including the time it took for patients to return to their baseline GLS score after their treatment, the duration of effect for a patient with at least a one-point GLS improvement, and the time it took a patient to return to their baseline using the Global Aesthetic Improvement Scale. The adverse events profile was similar across all three arms and overall 88.9% of adverse events were rated as mild and there were no serious adverse events. Jeuveau® is approved for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown (glabellar lines) in adults below 65 years of age. Through the company’s TRANSPARENCY Clinical Program, Jeuveau® was clinically proven to temporarily improve moderate to severe glabellar lines or “11’s” in adults and included the largest head-to-head pivotal study versus BOTOX®. The product is approved for sale in the U.S. under the brand name Jeuveau® and in Europe and Canada under the brand name Nuceiva®,and received regulatory approval in Australia in January 2023. 공고 • Oct 26
Evolus, Inc. to Report Q3, 2023 Results on Nov 07, 2023 Evolus, Inc. announced that they will report Q3, 2023 results After-Market on Nov 07, 2023 공고 • Aug 22
Evolus, Inc. Appoints Tomoko Yamagishi-Dressler as Chief Marketing Officer Evolus, Inc. has named Ms. Tomoko Yamagishi-Dressler as Chief Marketing Officer (CMO), effective August 21, 2023. Yamagishi-Dressler is an accomplished executive with more than two decades of established excellence leading omnichannel marketing for global beauty companies. A true strategist, Yamagishi-Dressler has successfully driven profitable business growth and increased equity for an iconic portfolio of industry brands. Most recently, Yamagishi-Dressler was Global Chief Marketing Officer at Beautyblender where she elevated Beautyblender’s global market position and drove category leaership for the brand’s namesake makeup tool in Sephora and ULTA stores across the United States. From 2000 to 2020, Yamagishi-Dressler held roles of increasing responsibility at Shiseido, one of the world’s top 5 beauty companies. During her tenure, Yamagishi-Dressler relocated to Shiseido’s headquarters in Japan in the appointed role of Group Leader for Global Skincare Marketing. While overseas, she introduced a new portfolio of products to strengthen the company’s competitive industry position.Following, Yamagishi-Dressler returned to the United States as Senior Vice President of Marketing & Sales, overseeing the digital transformation of the company and responsible for sales, e-commerce, marketing and media for Shiseido’s ultra-prestige division. Earlier in her career, Yamagishi-Dressler worked at Chanel Inc. and Victoria’s Secret Beauty Company. Yamagishi-Dressler is a graduate of the prestigious MBA program at Harvard Business School. Recent Insider Transactions • Aug 18
President recently sold US$152k worth of stock On the 16th of August, David Moatazedi sold around 15k shares on-market at roughly US$10.27 per share. This transaction amounted to 13% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was David's only on-market trade for the last 12 months. 공고 • Aug 09
Evolus, Inc. Unveils New Branding for Product Jeuveau to Reflect Growing and Evolving Consumers Evolus, Inc. unveiled fresh, new branding for its neurotoxin product, Jeuveau® (prabotulinumtoxinA-xvfs), showcased in the brand’s marketing campaign and on Jeuveau.com. Jeuveau® stands as the single most successful new aesthetic product launched in the United States since 2019 and intends to continue this trajectory, re-branding to break further away from the outdated tone, look and feel traditionally seen in the neurotoxin market. The new Jeuveau® imagery reflects today’s consumers, rejecting the traditional female-focused archetype, and celebrates the spectrum of beauty represented within the product’s growing contingent of loyal consumers – many of whom are millennials and younger. Inspired by this demographic, as well as the growing number of men turning to treatments to achieve a youthful, toned, and vibrant aesthetic, the “Jeuveau®, You See Me” marketing campaign uses inclusive messaging to encourage consumers of all genders to live unapologetically and embrace their beauty. New Risk • Aug 04
New major risk - Negative shareholders equity The company has negative equity. Total equity: -US$7.0m This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Negative equity (-US$7.0m). Minor Risk Less than 1 year of cash runway based on current free cash flow (-US$63m). Reported Earnings • Aug 03
Second quarter 2023 earnings released: US$0.32 loss per share (vs US$0.42 loss in 2Q 2022) Second quarter 2023 results: US$0.32 loss per share (improved from US$0.42 loss in 2Q 2022). Revenue: US$49.3m (up 33% from 2Q 2022). Net loss: US$18.1m (loss narrowed 23% from 2Q 2022). Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Pharmaceuticals industry in the United Kingdom. 공고 • Jul 29
Evolus, Inc. Revises Revenue Guidance for the Year 2023 Evolus, Inc. revised revenue guidance for the year 2023. The company raised 2023 revenue guidance from $180 million to $190 million to $185 million to $195 million. 공고 • Jun 30
Evolus Launches Nuceiva (Botulinum Toxin Type A) in Italy Evolus, Inc. has commenced the commercial launch of Nuceiva (botulinum toxin type A) in Italy. The product is now available for direct order and delivery to customers. Nuceiva is approved by the European Commission for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown (glabellar lines), when the severity of the above facial lines has an important psychological impact in adults below 65 years of age. Evolus is partnering with GP Dermal Solution, a pioneering company in the Italian cosmetic and wellness sector. Working closely with their suppliers, GP Dermal Solution delivers specialist products to aesthetics practitioners across Italy. In addition to Italy, Nuceiva is currently commercially available in Canada, Germany, Austria and Great Britain. The product is licensed in the United States under the brand name Jeuveau and in 2022, was the fastest growing neurotoxin in the U.S. market. The safety and efficacy of Nuceiva was evaluated through the company's TRANSPARENCY clinical program - three Phase III trials including the head-to-head aesthetic pivotal study versus Botox (onabotulinumtoxinA) to date, and two long-term safety studies. 공고 • Jun 23
Evolus Announces Successful Completion of Phase 2 Study Evaluating "Extra-Strength" Dose of Jeuveau (R) Evolus, Inc. announced the completion of its Phase 2 clinical study evaluating an "extra-strength" dose for extended duration of Jeuveau(R) (prabotulinumtoxinA-xvfs), its neurotoxin product and the first and only neurotoxin dedicated exclusively to aesthetics. Presentation of the full dataset will be planned for a medical meeting in Fourth Quarter 2023. Interim data presented at the 2023 International Master Course on Aging Science (IMCAS) World Congress showed Jeuveau Extra-Strength at 40U (units) demonstrated 6 months (26 weeks) duration across the three metrics presented, including the time it takes for patients to return to their baseline Glabellar Line Scale (GLS) score after their treatment, time back to baseline for patients with a response of none or mild on the GLS, and the duration of effect of at least a one- point GLS improvement. The adverse events profile across all three arms was similar. The severity rating demonstrated that 88% of the events were mild and 12% were moderate. Importantly, no serious adverse events were reported. The extra-strength glabellar line study is a multicenter, double-blind, randomized Phase 2 trial following 150 patients for up to 12 months or until the patient loses their correction. The study has three arms: Jeuveau Extra- Strength 40U and two active controls, BOTOX(R) 20U and Jeuveau 20U. Jeuveau is approved for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown (glabellar lines) in adults below 65 years of age. Through the company's TRANSPARENCY Clinical Program, Jeuveau was clinically proven to temporarily improve moderate to severe glabellar lines or "11's" in adults and included the largest head-to-head pivotal study versus BOTOX(R) . The product is approved for sale in the U.S. under the brand name Jeuveau and in Europe and Canada under the brand name Nuceiva(R), and has received regulatory approval in Australia in January 2023. Reported Earnings • May 10
First quarter 2023 earnings released: US$0.26 loss per share (vs US$0.31 loss in 1Q 2022) First quarter 2023 results: US$0.26 loss per share (improved from US$0.31 loss in 1Q 2022). Revenue: US$41.7m (up 23% from 1Q 2022). Net loss: US$14.8m (loss narrowed 16% from 1Q 2022). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 6.2% growth forecast for the Pharmaceuticals industry in the United Kingdom. 공고 • May 10
Evolus, Inc. Provides Revenue Guidance for the Year 2023 Evolus, Inc. provided revenue guidance for the year 2023. For the year, the company expects total net revenues for the full year 2023 to be between $180 million and $190 million, representing year-over-year growth of 21% to 28% and more than double the estimated growth rate of the aesthetic neurotoxin market. The company also assumes a return to industry seasonal revenue patterns. 공고 • May 06
Evolus, Inc. to Report Q1, 2023 Results on May 09, 2023 Evolus, Inc. announced that they will report Q1, 2023 results at 4:00 PM, US Eastern Standard Time on May 09, 2023 Board Change • Mar 31
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 7 experienced directors. No highly experienced directors. Independent Director Brady Stewart was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Mar 09
Full year 2022 earnings released: US$1.33 loss per share (vs US$0.94 loss in FY 2021) Full year 2022 results: US$1.33 loss per share (further deteriorated from US$0.94 loss in FY 2021). Revenue: US$148.6m (up 49% from FY 2021). Net loss: US$74.4m (loss widened 59% from FY 2021). Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Pharmaceuticals industry in the United Kingdom. 공고 • Jan 29
Evolus, Inc. Announces "Extra-Strength" Formulation of Jeuveau® Demonstrates Effects Lasting 26 Weeks in Interim Phase Ii Data Results, Representing Prolonged 6-Month Performance Evolus, Inc. presented interim data from its Phase II clinical study evaluating an "extra-strength" formulation for extended duration of Jeuveau® (prabotulinumtoxinA-xvfs), its neurotoxin product, at the 2023 International Master Course on Aging Science (IMCAS) World Congress in Paris. The data indicated that the “extra-strength” formulation of Jeuveau® at 40U (units) achieved a duration profile of 6 months or 26 weeks. The extra-strength glabellar line study is a multicenter, double-blind, randomized Phase 2 trial following 150 patients for up to 12 months or until the patient loses their correction. The study has three arms: Jeuveau® Extra-Strength 40U and two active controls, Botox® 20U and Jeuveau® 20U. An interim analysis was performed to assess the safety and efficacy of the extra-strength formulation. At this time, Jeuveau® Extra-Strength has demonstrated 6 months (26 weeks) duration across the three metrics presented, including the time it takes for patients to return to their baseline Glabellar Line Scale (GLS) score after their treatment, time back to baseline for patients with a response of none or mild on the GLS, and the duration of effect of at least a one-point GLS improvement. The adverse events profile across all three arms was similar. The severity rating demonstrated that 88% of the events were mild and 12% were moderate. Importantly, no serious adverse events were reported. Jeuveau® is approved for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown (glabellar lines) in adults below 65 years of age. The safety and efficacy of Jeuveau® was evaluated through the company’s TRANSPARENCY program, the largest head-to-head pivotal study versus BOTOX® to date. The product is approved for sale in the U.S. under the brand name Jeuveau® and in Canada under the brand name Nuceiva®, which launched in Europe in the second half of 2022, and received regulatory approval in Australia in January 2023. 공고 • Jan 24
Evolus, Inc. Receives Regulatory Approval for Nuceiva® in Australia Evolus, Inc. announced that the Australian Therapeutic Goods Administration (TGA) has provided regulatory approval for Nuceiva® (prabotulinumtoxinA)?, a neurotoxin dedicated exclusively to aesthetics. Nuceiva® was approved for the temporary improvement in the appearance of moderate to severe glabellar lines in adult patients. Glabellar lines are the vertical lines between the eyebrows seen at maximum frown. Evolus plans to launch Nuceiva® in Australia during the second half of 2023 after commencing additional launches in Europe – beginning with Germany and Austria – in the first half of 2023. In addition to Great Britain, Nuceiva® is also commercially available in Canada. The safety and efficacy of Nuceiva® was evaluated through the company’s global TRANSPARENCY clinical program, which included two Phase III U.S. trials, the large head-to-head aesthetic pivotal study versus BOTOX® (onabotulinumtoxinA) to date, and two long-term safety studies. The product is approved for sale in the U.S. under the brand name Jeuveau®. 공고 • Jan 19
Evolus, Inc. Provides Earnings Guidance for the Year 2023 Evolus, Inc. provided earnings guidance for the year 2023. For the year, the company total net revenues are estimated to be between $180 million and $190 million. Board Change • Jan 18
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 7 experienced directors. No highly experienced directors. Independent Director Brady Stewart was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Breakeven Date Change • Jan 04
Forecast to breakeven in 2025 The 7 analysts covering Evolus expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$19.7m in 2025. Average annual earnings growth of 61% is required to achieve expected profit on schedule. Board Change • Jan 04
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 7 experienced directors. No highly experienced directors. Independent Director Brady Stewart was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Nov 25
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 7 experienced directors. No highly experienced directors. Independent Director Brady Stewart was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Oct 07
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 7 experienced directors. No highly experienced directors. Independent Director Brady Stewart was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Recent Insider Transactions • Sep 07
Independent Director recently bought US$91k worth of stock On the 6th of September, Peter Farrell bought around 10k shares on-market at roughly US$9.10 per share. This transaction amounted to 29% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Despite this recent purchase, insiders have collectively sold US$1.7m more in shares than they bought in the last 12 months. Breakeven Date Change • Aug 04
Forecast to breakeven in 2024 The 7 analysts covering Evolus expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 11% per year to 2023. The company is expected to make a profit of US$633.3k in 2024. Average annual earnings growth of 69% is required to achieve expected profit on schedule. Reported Earnings • Aug 03
Second quarter 2022 earnings released: US$0.42 loss per share (vs US$0.30 loss in 2Q 2021) Second quarter 2022 results: US$0.42 loss per share (down from US$0.30 loss in 2Q 2021). Revenue: US$37.2m (up 42% from 2Q 2021). Net loss: US$23.5m (loss widened 50% from 2Q 2021). Over the next year, revenue is forecast to grow 35% compared to a 2.3% decline forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. Board Change • Aug 02
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 7 experienced directors. No highly experienced directors. Independent Director Brady Stewart was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Recent Insider Transactions • May 19
Independent Director recently sold US$138k worth of stock On the 16th of May, David Gill sold around 10k shares on-market at roughly US$13.35 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of US$2.5m more than they bought in the last 12 months. Reported Earnings • May 11
First quarter 2022 earnings released: US$0.31 loss per share (vs US$0.17 profit in 1Q 2021) First quarter 2022 results: US$0.31 loss per share (down from US$0.17 profit in 1Q 2021). Revenue: US$33.9m (up 177% from 1Q 2021). Net loss: US$17.5m (down 373% from profit in 1Q 2021). Over the next year, revenue is forecast to grow 35%, compared to a 5.3% growth forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings. Reported Earnings • Mar 05
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: US$0.94 loss per share (up from US$4.83 loss in FY 2020). Revenue: US$99.7m (up 76% from FY 2020). Net loss: US$46.8m (loss narrowed 71% from FY 2020). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 49%, compared to a 13% growth forecast for the pharmaceuticals industry in the United Kingdom. Breakeven Date Change • Jan 01
Forecast to breakeven in 2024 The 6 analysts covering Evolus expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$22.4m in 2024. Average annual earnings growth of 53% is required to achieve expected profit on schedule. Reported Earnings • Nov 03
Third quarter 2021 earnings released: US$0.35 loss per share (vs US$0.34 loss in 3Q 2020) The company reported a mediocre third quarter result with increased losses and weaker control over costs, although revenues improved. Third quarter 2021 results: Revenue: US$26.7m (up 51% from 3Q 2020). Net loss: US$19.4m (loss widened 70% from 3Q 2020). Breakeven Date Change • Sep 23
Forecast to breakeven in 2023 The 6 analysts covering Evolus expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$22.7m in 2023. Average annual earnings growth of 61% is required to achieve expected profit on schedule. 
